157 results
Page 3 of 8
S-8
b8ne o87rdjs
11 Mar 21
Registration of securities for employees
4:42pm
S-8
EX-23.2
x43lw
11 Mar 21
Registration of securities for employees
4:42pm
S-8
EX-5.1
s0104i31 fl8
11 Mar 21
Registration of securities for employees
4:42pm
8-K
EX-10.1
no8n4ckujp y4chr
1 Mar 21
Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:28pm
8-K
EX-5.1
90gat uaw0dsu5wrxh
1 Mar 21
Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:28pm
8-K
EX-4.1
rn0mde73pqbcx4gvog1u
1 Mar 21
Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:28pm
8-K
EX-4.2
mycqaqj y49jlw4
1 Mar 21
Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:28pm
424B5
p3fdv3k5vape pzydw
1 Mar 21
Prospectus supplement for primary offering
5:23pm
8-K
cblqek09g3m 1v
26 Feb 21
Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer
4:41pm
8-K
EX-5.1
fu52jwfj2k ggt
14 Dec 20
Nabriva Therapeutics Announces Proposed Public Offering
4:25pm
8-K
EX-10.1
chgx79xr 32fn1
14 Dec 20
Nabriva Therapeutics Announces Proposed Public Offering
4:25pm
424B5
gat64dhb8wn072zje
11 Dec 20
Prospectus supplement for primary offering
5:26pm
424B5
q4lkayvvrbmbak0zklp
10 Dec 20
Prospectus supplement for primary offering
5:19pm
8-K
EX-5.1
f3q6jl1rnbjyh
1 Sep 20
Other Events
5:02pm